NCT03703466
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have prior treatment with chemotherapy for locally advanced or metastatic disease
Exclusions: Patients with prior treatment of a CDK4/6 inhibitor (e.g. Ibrance/palbociclib, Verzenio/abemaciclib, Kisqali/ribociclib); Patients with symptomatic central nervous system (CNS) malignancy or metastasis
https://ClinicalTrials.gov/show/NCT03703466